Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., May 6, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

"If approved, BYDUREON will be the first once-weekly treatment for type 2 diabetes, and we are committed to making this important therapeutic option available to patients as soon as possible," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "We will continue to work closely with the agency through this final stage of the review process."

The new drug application (NDA) for BYDUREON was submitted in May 2009 and was based on data from the DURATION clinical trial program, as well as more than seven years of clinical experience with BYETTA® (exenatide) injection. The agency issued a complete response letter to the companies in March 2010 and the companies responded to that letter in April 2010.

BYDUREON (pronounced by-DUR-
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... York, NY (PRWEB) November 20, 2014 ... is now available as an open access journal featuring ... with infrared fluorescent proteins to preserve photoresponsiveness in the ... Two-color fluorescent in situ hybridization using chromogenic substrates ... chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. ... that it has closed a brokered private placement ... approximately C$3.7 million.  Cormark Securities Inc. and Clarus ... Brokered Offering for a syndicate of agents that ... Corp. (collectively the "Agents"). Concurrently with the Brokered ...
(Date:11/18/2014)... Nov. 18, 2014 Cord Blood Registry® (CBR®) ... the 10th Annual World Stem Cell Summit, the largest global ... 2014 World Stem Cell Summit will be held December 3-5 ... . The World Stem Cell ... lifesaving cures and therapies, convening the most prominent figures in ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... Critical step in determining cardiac safety of new drugs, ... the completion of its 100th Thorough QT Study.,QT has ... prolongation of QTc is a known surrogate for assessing ... Thorough QT Studies as one of the,centralized ECG services ...
... to Debut at NASS, GREENVILLE, N.C. and WOBURN, ... the U.S. market release of their,FortrOss bone graft substitute. ... 23rd Annual Meeting of the North American Spine Society ... the power of,nanotechnology for orthopaedic applications, is a scaffold ...
... Neb., Oct. 14 LI-COR Biosciences introduces a,new, ... the Odyssey(R),Infrared Imaging system. The Odyssey Two-Color Protein ... 700 and 800 nm channels of the,Odyssey System. ... gels,and can be used to visualize the progress ...
Cached Biology Technology:eRT Completes Milestone 100th Thorough QT Study 2eRT Completes Milestone 100th Thorough QT Study 3Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler 2LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker 2
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... the Max Planck Institute for Polymer Research (MPI-P) in ... a mineral content of almost 90 percent, yet extremely ... sea sponges and recreated the sponge spicules using the ... sponge. Natural minerals are usually very hard and prickly, ...
... termites, bed bugs and Argentine ants be effectively controlled? What ... And what are some ways to address the rodent ... for both the public interested in these questions and professionals ... University of California, Riverside on March 26, from 7:15 a.m. ...
... Biologists since Aristotle have puzzled over the reasons for ... of up to several hundred individuals drive themselves up ... shed some light on whether family relationships play a ... otherwise healthy whales. One hypothesis regarding the ...
Cached Biology News:Inspired by deep sea sponges: Creating flexible minerals 2Annual Urban Pest Management Conference set for March 26 2Oh mother, where art thou? 2Oh mother, where art thou? 3
... a simple and efficient means for isolation ... using annexin V magnetic beads (MagBeads). Annexin ... with high affinity for phosphatidylseri The ... and efficient means for isolation of apoptotic ...
... A tracking dye for nucleic acid ... including DNA sequencing. Preparation Quantity Equivalency: ... recommended. A 2% stock solution can ... Chem comp: Dye content ~ ...
... The VSOS-4 Orbital Shaker is designed to be ... a uniform motion that is both mixing and ... Orbital Shaker provides a smooth, quiet, reproducible and ... wide range of laboratory applications such as cell/tissue ...
... Biometra TProfessional Thermocycler combines top performance with ... achieves high speed and unparalleled temperature uniformity. ... providing programming in a spreadsheet or alternatively ... Smart Lid opens on the push of ...
Biology Products: